Lung
NVL-330-01
A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients with Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Trial overview
Clinical Area
Medical Oncology
Disease
Non-small cell lung cancer (NSCLC)
Disease site
Lung & bronchus
Study Phase
I
Trial Identifiers
Registration number: NCT06521554
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries